{"organizations": [], "uuid": "c113e7325d2f4a3bb872376fa89a60eb87be2eaf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180402.html", "section_title": "Archive News &amp; Video for Monday, 02 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/allergan-restructuring/allergan-plans-options-for-womens-health-unit-bloomberg-idUSL4N1RF51E", "country": "US", "domain_rank": 408, "title": "Allergan plans options for women's health unit - Bloomberg", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.057, "site_type": "news", "published": "2018-04-03T04:06:00.000+03:00", "replies_count": 0, "uuid": "c113e7325d2f4a3bb872376fa89a60eb87be2eaf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/allergan-restructuring/allergan-plans-options-for-womens-health-unit-bloomberg-idUSL4N1RF51E", "ord_in_thread": 0, "title": "Allergan plans options for women's health unit - Bloomberg", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "shounak dasgupta", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "allergan", "sentiment": "negative"}, {"name": "bloomberg", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2 (Reuters) - Allergan Plc is considering options for its womenâ€™s health unit, Bloomberg reported on Monday, citing people with knowledge of the matter.\nA sale, which would likely attract interest from private equity firms, could value the business at more than $5 billion, according to the Bloomberg report. ( bloom.bg/2pYuzK9 )\nAllergan did not immediately respond to a request for comment. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://bloom.bg/2pYuzK9", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T04:06:00.000+03:00", "crawled": "2018-04-03T16:22:51.022+03:00", "highlightTitle": ""}